Association of FUT2 and ABO with Crohn’s disease in Koreans.

Association of FUT2 and ABO with Crohn’s disease in Koreans. J Gastroenterol Hepatol. 2019 Jul 01;: Authors: Ye BD, Kim BM, Jung S, Lee HS, Hong M, Kim K, Moon JW, Baek J, Oh EH, Hwang SW, Park SH, Yang SK, Song K Abstract BACKGROUND AND AIMS: Fucosyltransferase 2 (FUT2) at 19q13 is a well-established susceptibility locus for Crohn’s disease (CD) in Caucasians. FUT2 encodes α-1,2-fucosyltransferase that regulates the secretion of the ABO antigens in both gastrointestinal mucosa and secretory glands. Given that Crohn’s disease is thought to arise from…

Read More

Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.

Related Articles Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Jun 06;: Authors: Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A Abstract BACKGROUND AND AIM: Vedolizumab (VDZ) has been used in inflammatory bowel disease (IBD) patients who failed anti-tumor necrosis factor (TNF) therapy. This study was to examine long-term outcome of IBD patients switching…

Read More

Effects of smoking on the association of HLA with ulcerative colitis.

Effects of smoking on the association of HLA with ulcerative colitis. J Gastroenterol Hepatol. 2019 Apr 30;: Authors: Lee HS, Kim K, Jung S, Hong M, Kim BM, Yoo DS, Moon JW, Baek J, Hwang SW, Park SH, Yang SK, Han B, Song K, Ye BD Abstract BACKGROUND AND AIM: Tobacco smoking is a risk factor for gastrointestinal disorders, causing mucosal damage and impairing immune responses. However, smoking has been found to be protective against ulcerative colitis (UC). Human leukocyte antigen (HLA) is a major susceptibility locus for UC, and…

Read More

Association of TRAP1 with Infliximab-Induced Mucosal Healing in Crohn’s disease.

Association of TRAP1 with Infliximab-Induced Mucosal Healing in Crohn’s disease. J Gastroenterol Hepatol. 2019 Apr 30;: Authors: Park SH, Hong M, Lee HS, Ye BD, Hwang SW, Jung S, Baek J, Moon J, Kim BM, Oh SH, Kim KM, Lee I, Im CN, Liu J, McGovern DPB, Yang SK, Song K Abstract BACKGROUND AND AIM: Anti-tumour necrosis factor (TNF) agents, such as infliximab (IFX), have been increasingly used to induce and maintain disease remission in patients with Crohn’s disease (CD). Despite a considerable non-response rate, little is known about the…

Read More

Remission Induction, Maintenance, and Endoscopic Outcome with Oral 5-Aminosalicylic Acid in Intestinal Behçet’s Disease.

Remission Induction, Maintenance, and Endoscopic Outcome with Oral 5-Aminosalicylic Acid in Intestinal Behçet’s Disease. J Gastroenterol Hepatol. 2019 Apr 24;: Authors: Kinoshita H, Nishioka H, Ikeda A, Ikoma K, Sameshima Y, Ohi H, Tatsuno M, Kouyama J, Kawamoto C, Mitsui T, Tamura Y, Hashimoto Y, Nishio M, Ogashiwa T, Saigusa Y, Maeda S, Kimura H, Kunisaki R, Koike K Abstract BACKGROUND AND AIM: Oral 5-aminosalicylic acid (5-ASA) is recommended for the therapy of mild to moderate intestinal Behçet’s disease (BD). However, the induction remission efficacy and endoscopic outcomes of 5-ASA…

Read More

The usefulness of intestinal real-time virtual sonography in patients with inflammatory bowel disease.

The usefulness of intestinal real-time virtual sonography in patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2019 Apr 01;: Authors: Kawai S, Iijima H, Shinzaki S, Hiyama S, Yamaguchi T, Araki M, Iwatani S, Shiraishi E, Mukai A, Inoue T, Tsujii Y, Hayashi Y, Tsujii M, Takehara T Abstract BACKGROUND AND AIM: Trans-abdominal ultrasonography (US) examination for the intestine is often difficult and its precedence for intestinal examination depends on accessibility to experienced ultrasonographers. Real-time virtual sonography (RVS) assists examination of US as a fusion method by synchronizing US images…

Read More

Epidemiology, characteristics and survival of post-colonoscopy colorectal cancer in Asia: a population-based study.

Epidemiology, characteristics and survival of post-colonoscopy colorectal cancer in Asia: a population-based study. J Gastroenterol Hepatol. 2019 Apr 01;: Authors: Cheung KS, Chen L, Seto WK, Leung WK Abstract BACKGROUND AND AIMS: Population-based studies on post-colonoscopy colorectal cancer (CRC) from Asia are sparse. We aimed to determine the characteristics and predictive factors and survival of post-colonoscopy CRC in Hong Kong. METHODS: This is a territory-wide retrospective cohort study. Patients aged ≥40 years with colonoscopies performed between 2005 and 2013 without history of CRCs, inflammatory bowel disease and prior colectomy were…

Read More

ZNF133 Is Associated with Infliximab Responsiveness in Patients with Inflammatory Bowel Diseases.

ZNF133 Is Associated with Infliximab Responsiveness in Patients with Inflammatory Bowel Diseases. J Gastroenterol Hepatol. 2019 Mar 09;: Authors: Jung ES, Choi KW, Kim SW, Hübenthal M, Mucha S, Park J, Park Z, Ellinghaus D, Schreiber S, Franke A, Oh WY, Cheon JH Abstract BACKGROUND AND AIM: Infliximab has been widely prescribed for treating inflammatory bowel disease (IBD). However, the response rates to infliximab differ among patients. Therefore, we aimed to identify the genetic and clinical markers that predict infliximab response. METHODS: A total of 139 Korean patients with IBD…

Read More

Best practices on immunomodulators and biological agents for Ulcerative colitis and Crohn’s disease in Asia.

Best practices on immunomodulators and biological agents for Ulcerative colitis and Crohn’s disease in Asia. J Gastroenterol Hepatol. 2019 Mar 08;: Authors: Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Raja Ali RA, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL,…

Read More

Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.

Related Articles Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol. 2019 Mar 03;: Authors: Kim NH, Lee JH, Hong SN, Yoon H, Kang HW, Lee SH, Im JP, Cha JM, Eun CS, Kim JW, Choi CH, Park DI Abstract BACKGROUND AND AIM: A biosimilar of infliximab, CT-P13 (Remsima®) has the potential to reduce treatment costs and enhance access to biological therapy for inflammatory bowel disease (IBD) patients. However, long-term clinical data on its use for…

Read More
<< Go Back